219 related articles for article (PubMed ID: 32193547)
1. Multiparametric MRI for early identification of therapeutic response in recurrent glioblastoma treated with immune checkpoint inhibitors.
Song J; Kadaba P; Kravitz A; Hormigo A; Friedman J; Belani P; Hadjipanayis C; Ellingson BM; Nael K
Neuro Oncol; 2020 Nov; 22(11):1658-1666. PubMed ID: 32193547
[TBL] [Abstract][Full Text] [Related]
2. Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitors.
Hagiwara A; Oughourlian TC; Cho NS; Schlossman J; Wang C; Yao J; Raymond C; Everson R; Patel K; Mareninov S; Rodriguez FJ; Salamon N; Pope WB; Nghiemphu PL; Liau LM; Prins RM; Cloughesy TF; Ellingson BM
Neuro Oncol; 2022 Jun; 24(6):1020-1028. PubMed ID: 34865129
[TBL] [Abstract][Full Text] [Related]
3. Quantitative Evaluation of Diffusion and Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Differentiation Between Primary Central Nervous System Lymphoma and Glioblastoma.
Lu S; Wang S; Gao Q; Zhou M; Li Y; Cao P; Hong X; Shi H
J Comput Assist Tomogr; 2017; 41(6):898-903. PubMed ID: 28806317
[TBL] [Abstract][Full Text] [Related]
4. Identification of Early Response to Anti-Angiogenic Therapy in Recurrent Glioblastoma: Amide Proton Transfer-weighted and Perfusion-weighted MRI compared with Diffusion-weighted MRI.
Park JE; Kim HS; Park SY; Jung SC; Kim JH; Heo HY
Radiology; 2020 May; 295(2):397-406. PubMed ID: 32154775
[TBL] [Abstract][Full Text] [Related]
5. Imaging biomarkers guided anti-angiogenic therapy for malignant gliomas.
Kong Z; Yan C; Zhu R; Wang J; Wang Y; Wang Y; Wang R; Feng F; Ma W
Neuroimage Clin; 2018; 20():51-60. PubMed ID: 30069427
[TBL] [Abstract][Full Text] [Related]
6. Multiparametric MRI for Differentiation of Radiation Necrosis From Recurrent Tumor in Patients With Treated Glioblastoma.
Nael K; Bauer AH; Hormigo A; Lemole M; Germano IM; Puig J; Stea B
AJR Am J Roentgenol; 2018 Jan; 210(1):18-23. PubMed ID: 28952810
[TBL] [Abstract][Full Text] [Related]
7. Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma.
Thomas AA; Arevalo-Perez J; Kaley T; Lyo J; Peck KK; Shi W; Zhang Z; Young RJ
J Neurooncol; 2015 Oct; 125(1):183-90. PubMed ID: 26275367
[TBL] [Abstract][Full Text] [Related]
8. Response Assessment in Neuro-Oncology criteria, contrast enhancement and perfusion MRI for assessing progression in glioblastoma.
Tensaouti F; Khalifa J; Lusque A; Plas B; Lotterie JA; Berry I; Laprie A; Cohen-Jonathan Moyal E; Lubrano V
Neuroradiology; 2017 Oct; 59(10):1013-1020. PubMed ID: 28842741
[TBL] [Abstract][Full Text] [Related]
9. Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging--pilot study.
Sawlani RN; Raizer J; Horowitz SW; Shin W; Grimm SA; Chandler JP; Levy R; Getch C; Carroll TJ
Radiology; 2010 May; 255(2):622-8. PubMed ID: 20413772
[TBL] [Abstract][Full Text] [Related]
10. Differentiation of solitary brain metastasis from glioblastoma multiforme: a predictive multiparametric approach using combined MR diffusion and perfusion.
Bauer AH; Erly W; Moser FG; Maya M; Nael K
Neuroradiology; 2015 Jul; 57(7):697-703. PubMed ID: 25845813
[TBL] [Abstract][Full Text] [Related]
11. Bidirectional Contrast agent leakage correction of dynamic susceptibility contrast (DSC)-MRI improves cerebral blood volume estimation and survival prediction in recurrent glioblastoma treated with bevacizumab.
Leu K; Boxerman JL; Lai A; Nghiemphu PL; Pope WB; Cloughesy TF; Ellingson BM
J Magn Reson Imaging; 2016 Nov; 44(5):1229-1237. PubMed ID: 26971534
[TBL] [Abstract][Full Text] [Related]
12. Utility of apparent diffusion coefficient in predicting the outcome of Gamma Knife-treated brain metastases prior to changes in tumor volume: a preliminary study.
Goldman M; Boxerman JL; Rogg JM; Norén G
J Neurosurg; 2006 Dec; 105 Suppl():175-82. PubMed ID: 18503353
[TBL] [Abstract][Full Text] [Related]
13. Value of dynamic contrast perfusion MRI to predict early response to bevacizumab in newly diagnosed glioblastoma: results from ACRIN 6686 multicenter trial.
Schmainda KM; Prah MA; Marques H; Kim E; Barboriak DP; Boxerman JL
Neuro Oncol; 2021 Feb; 23(2):314-323. PubMed ID: 32678438
[TBL] [Abstract][Full Text] [Related]
14. Demonstration of DCE-MRI as an early pharmacodynamic biomarker of response to VEGF Trap in glioblastoma.
O'Neill AF; Qin L; Wen PY; de Groot JF; Van den Abbeele AD; Yap JT
J Neurooncol; 2016 Dec; 130(3):495-503. PubMed ID: 27576699
[TBL] [Abstract][Full Text] [Related]
15. Multiparametric imaging-based differentiation of lymphoma and glioblastoma: using T1-perfusion, diffusion, and susceptibility-weighted MRI.
Saini J; Kumar Gupta P; Awasthi A; Pandey CM; Singh A; Patir R; Ahlawat S; Sadashiva N; Mahadevan A; Kumar Gupta R
Clin Radiol; 2018 Nov; 73(11):986.e7-986.e15. PubMed ID: 30197047
[TBL] [Abstract][Full Text] [Related]
16. Interval Change in Diffusion and Perfusion MRI Parameters for the Assessment of Pseudoprogression in Cerebral Metastases Treated With Stereotactic Radiation.
Knitter JR; Erly WK; Stea BD; Lemole GM; Germano IM; Doshi AH; Nael K
AJR Am J Roentgenol; 2018 Jul; 211(1):168-175. PubMed ID: 29708785
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of relative cerebral blood volume in patients with recurrent glioblastoma multiforme treated with bevacizumab.
Stecco A; Amatuzzo P; Sponghini AP; Platini F; Quagliozzi M; Buemi F; Guenzi E; Carriero A
J Neurosurg Sci; 2019 Aug; 63(4):394-401. PubMed ID: 27603407
[TBL] [Abstract][Full Text] [Related]
18. Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.
Schmainda KM; Zhang Z; Prah M; Snyder BS; Gilbert MR; Sorensen AG; Barboriak DP; Boxerman JL
Neuro Oncol; 2015 Aug; 17(8):1148-56. PubMed ID: 25646027
[TBL] [Abstract][Full Text] [Related]
19. Prognosis prediction of non-enhancing T2 high signal intensity lesions in glioblastoma patients after standard treatment: application of dynamic contrast-enhanced MR imaging.
Kim R; Choi SH; Yun TJ; Lee ST; Park CK; Kim TM; Kim JH; Park SW; Sohn CH; Park SH; Kim IH
Eur Radiol; 2017 Mar; 27(3):1176-1185. PubMed ID: 27357131
[TBL] [Abstract][Full Text] [Related]
20. Interobserver variability in the radiological assessment of magnetic resonance imaging (MRI) including perfusion MRI in glioblastoma multiforme.
Kerkhof M; Hagenbeek RE; van der Kallen BF; Lycklama À Nijeholt GJ; Dirven L; Taphoorn MJ; Vos MJ
Eur J Neurol; 2016 Oct; 23(10):1528-33. PubMed ID: 27424939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
